The Emerging Role of Inflammation and Fibrosis in Atrial Fibrillation and the Potential of Counter Interventions
DOI:
https://doi.org/10.2015/hc.v3i1%20sup.140Abstract
Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice, affecting approximately 0.9% of the population. The prevalence of AF is strongly age-dependent, affecting approximately 1% of persons aged 65 years and 5% of individuals older than 65 years.2 AF is also associated with an increase in the relative risk of mortality ranging from 1.3 to 2.34, independent of other risk factors as well as an increasing morbidity and adversely affects quality of life.3-5 Unfortunately, current rhythm control strategies are far from ideal. Data from five comparative studies of a primary rate control vs. rhythm control strategy for patients with a history of AF failed to show a significant superiority of rhythm control. In fact, these studies merely emphasized the limited efficacy and high side-effect profile of the currently available anti-arrhythmic drugs.Downloads
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).